JP2009517403A - Ｐａｒｐ−１阻害剤の使用 - Google Patents

Ｐａｒｐ−１阻害剤の使用 Download PDF

Info

Publication number
JP2009517403A
JP2009517403A JP2008542534A JP2008542534A JP2009517403A JP 2009517403 A JP2009517403 A JP 2009517403A JP 2008542534 A JP2008542534 A JP 2008542534A JP 2008542534 A JP2008542534 A JP 2008542534A JP 2009517403 A JP2009517403 A JP 2009517403A
Authority
JP
Japan
Prior art keywords
composition
parp
inhibitor
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008542534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517403A5 (https=
Inventor
キャスリーン エイ． スコット
マイケル マンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of JP2009517403A publication Critical patent/JP2009517403A/ja
Publication of JP2009517403A5 publication Critical patent/JP2009517403A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008542534A 2005-11-25 2006-11-27 Ｐａｒｐ−１阻害剤の使用 Pending JP2009517403A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73953605P 2005-11-25 2005-11-25
PCT/US2006/061254 WO2007062413A2 (en) 2005-11-25 2006-11-27 Use of parp-1 inhibitors

Publications (2)

Publication Number Publication Date
JP2009517403A true JP2009517403A (ja) 2009-04-30
JP2009517403A5 JP2009517403A5 (https=) 2010-01-14

Family

ID=38068066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542534A Pending JP2009517403A (ja) 2005-11-25 2006-11-27 Ｐａｒｐ−１阻害剤の使用

Country Status (9)

Country Link
US (1) US20090170860A1 (https=)
EP (1) EP1962843B1 (https=)
JP (1) JP2009517403A (https=)
AT (1) ATE499098T1 (https=)
AU (1) AU2006318226A1 (https=)
CA (1) CA2630900A1 (https=)
DE (1) DE602006020335D1 (https=)
ES (1) ES2361566T3 (https=)
WO (1) WO2007062413A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
EP1365808B1 (en) * 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
DK1827500T3 (da) * 2004-10-26 2009-08-31 Pharma Mar Sa Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009047752A1 (en) * 2007-10-09 2009-04-16 Ramot At Tel-Aviv University Ltd. Breast cancer therapy
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
ES2595240T3 (es) 2012-07-09 2016-12-28 Lupin Limited Derivados de tetrahidroquinazolinona como inhibidores de PARP
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN108368059B (zh) * 2016-04-18 2022-02-01 深圳市塔吉瑞生物医药有限公司 一种取代的酞嗪酮化合物及其药物组合物
KR20180097876A (ko) * 2017-02-24 2018-09-03 주식회사 온코크로스 1,5-이소퀴놀린디올을 포함하는 피부 노화 방지 및 주름 개선용 조성물
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517056A (ja) * 2000-11-06 2004-06-10 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
US20050020595A1 (en) * 2003-05-28 2005-01-27 Kalish Vincent J. Compounds, methods and pharmaceutical compositions for inhibiting PARP
WO2005012524A1 (en) * 2003-07-25 2005-02-10 The University Of Sheffield Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
WO2005097750A1 (en) * 2004-03-30 2005-10-20 Aventis Pharmaceuticals Inc. Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US20050187172A1 (en) * 2003-12-23 2005-08-25 Masferrer Jaime L. Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517056A (ja) * 2000-11-06 2004-06-10 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
US20050020595A1 (en) * 2003-05-28 2005-01-27 Kalish Vincent J. Compounds, methods and pharmaceutical compositions for inhibiting PARP
WO2005012524A1 (en) * 2003-07-25 2005-02-10 The University Of Sheffield Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
WO2005097750A1 (en) * 2004-03-30 2005-10-20 Aventis Pharmaceuticals Inc. Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)

Also Published As

Publication number Publication date
EP1962843A2 (en) 2008-09-03
CA2630900A1 (en) 2007-05-31
EP1962843B1 (en) 2011-02-23
EP1962843A4 (en) 2009-08-12
WO2007062413A2 (en) 2007-05-31
WO2007062413A3 (en) 2007-12-27
ATE499098T1 (de) 2011-03-15
DE602006020335D1 (de) 2011-04-07
ES2361566T3 (es) 2011-06-20
US20090170860A1 (en) 2009-07-02
AU2006318226A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
JP2009517403A (ja) Ｐａｒｐ−１阻害剤の使用
AU2019216351B2 (en) Combination therapy for the treatment of mastocytosis
RU2478387C2 (ru) ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
CN107087409B (zh) 苯并杂环化合物及其应用
JP2021004244A (ja) 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用
US8691777B2 (en) Combination therapy
US20160158186A1 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
KR102115047B1 (ko) 티로신 키나제 억제제들을 갖는 조합 제품 및 그의 용도
US20140378409A1 (en) Effect potentiator for antitumor agents
JP2016519684A (ja) 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
RU2474612C2 (ru) Индуцирование гибели клеток путем ингибирования адаптивного теплового шокового ответа
US20210283109A1 (en) Heterocyclic diamidines
US20130079401A1 (en) Novel use of isothiocyanates for treating cancer
WO2019207087A1 (en) Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor and an erk inhibitor and methods and use thereof
JP2003525255A (ja) ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
US20070207996A1 (en) Novel Compositions And Methods Of Treatment
WO2011016952A1 (en) Compositions and methods for treating cancer
US20130345231A1 (en) Anticancer therapeutic agents
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン
CN108853507A (zh) 一种抗肿瘤的增效药物组合物及其制备方法和用途
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
CN115038440A (zh) 使用chk抑制剂的癌症联合疗法
RU2844464C2 (ru) Фармацевтическая композиция для профилактики или лечения трижды негативного рака молочной железы
EP4069243B1 (en) Combinations of etc-159 and olaparib for use in the treatment of pancreatic cancer, ovarian cancer and cholangio-carcinomas
US20190247397A1 (en) Combinatory treatment strategies of cancer based on rna polymerase i inhibition

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121105